# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cannara Biotech Inc. announced on Monday its fiscal second quarter 2024 financial and operating results for the three and six-m...
Oppenheimer analyst Brian Nagel maintains Lovesac (NASDAQ:LOVE) with a Outperform and lowers the price target from $60 to $35.
Maxim Group analyst Tom Forte initiates coverage on Lovesac (NASDAQ:LOVE) with a Buy rating and announces Price Target of $36.
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
Canaccord Genuity analyst Maria Ripps maintains Lovesac (NASDAQ:LOVE) with a Buy and lowers the price target from $44 to $36.
Roth MKM analyst Matt Koranda maintains Lovesac (NASDAQ:LOVE) with a Buy and lowers the price target from $34 to $30.